Intellia Therapeutics (NTLA)
(Delayed Data from NSDQ)
$27.35 USD
+1.34 (5.15%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $27.56 +0.21 (0.77%) 6:24 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Brokerage Reports
Intellia Therapeutics, Inc. [NTLA]
Reports for Purchase
Showing records 201 - 220 ( 287 total )
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q20 - Progressing Platform with First Patient to Dose in 2020
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Authorized to Begin ATTR Human Trials. First Patient to Be Dosed in 2020.
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q20: Progressing Platform with the First Patient to Be Dosed in Late-2020
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q20 Financials; CTA Now Filed for NTLA-2001, Additional Filings in 2021
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Expands Collaboration With REGN to Further Develop Its Modular Platform
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Expanded Regeneron Collaboration a Positive for NTLA
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
AACR II 2020 Abstract Roundup for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q20 Financials; NTLA-2001 Nearing the Clinic for ATTR, but First, ASGCT
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q20: Broadening Footprint with In Vivo and Ex Vivo Therapies
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Ahead of the ASGCT 2020 Virtual Meeting - Read Through To Our Coverage
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
COVID-19 Impact on Coverage Universe: Week of April 20 Update
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D